Treatment of exudative age-related macular degeneration: many factors to consider.
Olsen
Timothy W
TW
Department of Ophthalmology, University of Minnesota, Minneapolis, MN 55455, USA. olsen010@umn.edu
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000191:economics; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage* / Q000191:economics; D000068258:Bevacizumab; D017281:Cost of Illness; D004195:Disease Models, Animal; D016527:Drug Costs; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics / Q000378:metabolism; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000378:metabolism; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab